XTNT

Xtant Medical Holdings, Inc. (XTNT) - Q2 2024 10-Q Summary

Business Context and Reporting Period

This Quarterly Report on Form 10-Q covers the period ended June 30, 2024. Xtant Medical Holdings, Inc. is a global medical technology company focused on orthobiologics and spinal implant systems. The company operates as a non-accelerated filer and a smaller reporting company. The reporting period reflects the integration of recent acquisitions, including Surgalign SPV, Surgalign Holdings assets, and nanOss production operations.

Key Financial Metrics

Note: Debt includes $11.9 million on the line of credit and $22.0 million on the term loan as of June 30, 2024.

Material Changes vs. Prior Period

• Revenue Growth: Revenue increased 48% year-over-year for Q2 and 51% for the six-month period, primarily driven by the contribution of the Surgalign Holdings hardware and biologics business acquired in 2023.
• Expense Increases: Operating expenses rose significantly. General and Administrative (G&A) expenses increased 56% (Q2) and 58% (YTD), while Sales and Marketing expenses increased 51% (Q2) and 63% (YTD). These increases are attributed to higher headcount, stock-based compensation, and commissions tied to revenue growth.
• Debt Structure: In May 2024, the company amended its term credit agreement to increase the borrowing capacity to $22.0 million, which was fully drawn. The revolving credit facility commitment was increased to $17.0 million.
• Product Mix: Orthobiologics revenue represented 54% of total revenue in Q2 2024, down from 71% in Q2 2023, while Spinal Implant revenue grew to 46% from 29%.

Guidance, Outlook, and Risks

• Liquidity Outlook: Management believes current cash ($5.5 million), anticipated operating cash flows, and available credit facilities ($5.1 million remaining on revolver) will fund operations through at least August 2025. However, the company may seek additional capital prior to that date.
• Recent Financing: On August 7, 2024, the company entered into a private placement agreement to sell 7.8 million shares for gross proceeds of $5.0 million to fund working capital.
• Internal Controls: The company disclosed that its disclosure controls and procedures were not effective as of June 30, 2024, due to two material weaknesses related to inventory valuation and consignment inventory verification stemming from recent acquisitions. Remediation is ongoing.
• Key Risks: Risks include the ability to achieve profitability, integration of acquired products, reliance on third-party suppliers, supply chain disruptions, and the need for additional financing. The company also faces risks related to foreign currency fluctuations and regulatory approvals.
• Management Changes: The Chief Commercial Officer position was eliminated effective August 16, 2024, with the CEO assuming the role of head of sales.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $5.5 million cash balance plus the $5.0 million private placement proceeds against the burn rate of ~$10.8 million in operating cash outflows for the first half of the year.
• Debt Covenants: Confirm continued compliance with the amended credit agreement covenants, specifically net product revenue requirements and liquidity levels.
• Inventory Valuation: Scrutinize the remediation of material weaknesses regarding inventory valuation and consignment inventory, as this directly impacts the accuracy of the balance sheet and cost of sales.
• Acquisition Integration: Assess the actual revenue contribution and margin impact of the Surgalign and nanOss acquisitions versus initial projections.
• Stock-Based Compensation: Monitor the impact of the new Performance Stock Units (PSUs) and existing RSUs on future operating expenses, with $4.2 million in unrecognized RSU costs and $2.4 million in unrecognized PSU costs.